DERMABOND PRINEO
Commercial- Indications
- Surgical wound closure
Company intelligence / Profile preview
Ethicon has a long history as the global leader in surgical sutures, wound closure devices, staplers, energy-based surgical instruments, hernia repair meshes/fixation systems, adjunctive hemostats for bleeding control during surgery, microwave ablation for tumors, and other advanced surgical solutions. Its products are used worldwide across virtually all major hospital operating rooms[1][6][8].
Ethicon's innovations include the first mass-produced sterile suture and pioneering sterilization by irradiation. The company continues to expand its portfolio with acquisitions in minimally invasive technologies[1][5].
Ethicon operates as part of Johnson & Johnson MedTech since September 2024[1].
Its clinical results are reflected in widespread adoption—e.g., an estimated ~80% U.S. market share for sutures—and broad use across more than fifty countries[1].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ethicon.